How accurate is the prediction of driving ability in a Parkinson’s clinic setting?
Objective: To determine whether routine clinical assessment (motor examination, cognitive assessment and global clinical impression) accurately predicts the ability of People with Parkinson's (PwP) to…Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of Pramipexole (PPX). Background: Parkinson's disease (PD) is characterized by both motor…The effect of walking speed on postural stability in Parkinson’s disease fallers
Objective: This cross-sectional study aimed to evaluate the effect of imposed faster and slower walking speeds on gait rhythmicity in people with Parkinson's disease (PD)…Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists
Objective: To investigate the association between dopamine receptor D types 2(DRD2) (CA)n and types 3 (DRD3) Ser9Gly polymorphisms and the risk of Parkinson's disease (PD),…Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study
Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease
Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…Parkinson patient reported outcomes of voice and communication pre, post and 6 months following LSVT LOUD® and LSVT ARTIC
Objective: To evaluate the functional impact of LSVT LOUD and LSVT ARTIC on voice and communication in individuals with Parkinson's disease (PD) immediately post and…Preclinical evaluation of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias: Is it a ‘chemical’ DBS?
Objective: To evaluate mechanism of long-term activity of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias (LID). Background: Ketamine is an anesthetic that, when administered as…Utilization and longitudinal impact of anticholinergic use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry
Objective: To evaluate baseline predictors and longitudinal impact of anticholinergics use in Parkinson's disease (PD). Background: Anticholinergics have beneficial effect on tremor in PD but…ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump
Objective: To characterize the local safety and PK of a novel apomorphine formulation, ND0701, in comparison to a commercially available apomorphine–HCl solution. Background: Apomorphine is…
- « Previous Page
- 1
- …
- 181
- 182
- 183
- 184
- 185
- …
- 207
- Next Page »